K-Cell Biotech Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
8
K-Cell Biotech General Information
Description
Developer of biopharmaceutical technology designed for vaccines.The company's vaccines include human rabies vaccine (chicken embryo fibroblast), new genotype MMR combination vaccine, inactivated rotavirus vaccine and respiratory syncytial virus vaccine, enabling users to improve human health.
Contact Information
Website
www.king-cell.comCorporate Office
- No. 1136, Langong Road
- Jinshan Industrial Park
- Shanghai
- China
Corporate Office
- No. 1136, Langong Road
- Jinshan Industrial Park
- Shanghai
- China
K-Cell Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 28-Oct-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 04-Jun-2021 | Completed | Generating Revenue |
K-Cell Biotech Patents
K-Cell Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022188783-A1 | Construction of f gene-replaced chimeric measles attenuated strain | Inactive | 10-Mar-2021 | ||
| WO-2022188784-A1 | Construction of h-gene-replaced chimeric measles attenuated strain | Inactive | 10-Mar-2021 | ||
| EP-4056983-A1 | Device for evaluating neurovirulence of mumps virus | Pending | 04-Nov-2019 | ||
| EP-4056983-A4 | Device for evaluating neurovirulence of mumps virus | Pending | 04-Nov-2019 | ||
| US-20220404359-A1 | Device for evaluating neurovirulence of mumps virus | Pending | 04-Nov-2019 | G01N1/30 |
K-Cell Biotech Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDH Investments | PE/Buyout | Minority | ||
| Dongwu Securities | Corporation | Minority | ||
| Haitong Securities (Shanghai) | Investment Bank | Minority | ||
| Shiyu Capital | Venture Capital | Minority | ||
| Zhenji Capital | Venture Capital | Minority |
K-Cell Biotech FAQs
-
When was K-Cell Biotech founded?
K-Cell Biotech was founded in 2017.
-
Where is K-Cell Biotech headquartered?
K-Cell Biotech is headquartered in Shanghai, China.
-
What industry is K-Cell Biotech in?
K-Cell Biotech’s primary industry is Drug Discovery.
-
Is K-Cell Biotech a private or public company?
K-Cell Biotech is a Private company.
-
What is K-Cell Biotech’s current revenue?
The current revenue for K-Cell Biotech is .
-
Who are K-Cell Biotech’s investors?
CDH Investments, Dongwu Securities, Haitong Securities (Shanghai), Shiyu Capital, and Zhenji Capital are 5 of 8 investors who have invested in K-Cell Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process